Adjournment of Board meeting and Detailed reasons for delay in submission of audited Financial results (Standalone & Consolidated) for the quarter and year ended 31st March 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indrayani Biotech has delayed the announcement of its audited financial results (standalone and consolidated) for the quarter and year ended 31st March 2025. Results were originally due to BSE by 30th May 2025, and a board meeting scheduled for 9th June 2025 has now been further postponed to 12th June 2025. The company cited delays in consolidating subsidiary results and completing internal and external audit processes as reasons for the adjournment. The trading window for designated persons will remain closed until 48 hours after the results are declared. The board meeting ran from 4:00 PM to 8:00 PM without approving the results.
This is a procedural/compliance delay with no financial data disclosed yet, so there is no direct impact on shareholders. However, repeated delays beyond SEBI's regulatory deadline may raise minor governance concerns and could attract scrutiny from the exchange.